Q1 EPS Forecast for Abeona Therapeutics Decreased by Analyst

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Abeona Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.36) per share for the quarter, down from their previous estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19.

A number of other analysts have also weighed in on the company. Oppenheimer initiated coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective on the stock. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $4.99 on Wednesday. The company has a market cap of $216.92 million, a P/E ratio of -1.86 and a beta of 1.79. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm’s 50 day moving average price is $5.43 and its 200 day moving average price is $5.82.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. grew its stake in shares of Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after purchasing an additional 652,366 shares in the last quarter. Western Standard LLC lifted its holdings in Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after buying an additional 386,321 shares during the last quarter. Jane Street Group LLC lifted its holdings in Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock worth $732,000 after buying an additional 118,262 shares during the last quarter. 683 Capital Management LLC boosted its position in shares of Abeona Therapeutics by 17.3% during the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after acquiring an additional 116,845 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Abeona Therapeutics in the 4th quarter valued at about $520,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.